Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest antibodies Stories

2012-05-16 06:26:53

NEW YORK, May 16, 2012 /PRNewswire/ -- Intellect Neurosciences, Inc. (OTCBB: ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced it has filed three new patent applications with the United States Patent and Trademark Office (USPTO), which expand the Company's immunotherapy pipeline. (Logo: http://photos.prnewswire.com/prnh/20111214/NY22484LOGO)...

2012-05-10 09:35:16

Researchers say 3 proteins linked to worse outcomes are found more often in blacks than Caucasians with a common form of scleroderma A new analysis finds that compared to Caucasians, African-Americans with systemic scleroderma have more antibodies in the blood that are linked to severe complications and an increased likelihood of death. They say this finding, published today in Arthritis & Rheumatism, suggests physicians can use these disease markers to screen and treat scleroderma...

2012-05-10 09:34:04

Antibodies associated with severe lung disease and decreased survival to blame African Americans have more severe complications from systemic sclerosis, also known as scleroderma, than Caucasians. Findings published today in, Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR), show that compared with Caucasians, African-American patients were more likely to have antibodies that increased frequency and severity of pulmonary fibrosis, which is associated with...

2012-05-08 09:45:39

Scientists at The Scripps Research Institute have made an important discovery about the internal programming of B cells, the immune cells that make antibodies against infections. The finding opens the way for the development of vaccines that can work more efficiently and hints at therapies for conditions in which B cells cause harm–such as the autoimmune disease lupus erythymatosus, severe allergies, and B-cell lymphomas. The discovery reveals that B cells produce special proteins to...

H1N1 Discovery Paves Way For Universal Flu Vaccine
2012-05-08 07:47:34

University of British Columbia researchers have found a potential way to develop universal flu vaccines and eliminate the need for seasonal flu vaccinations. Each year, seasonal influenza causes serious illnesses in three to five million people and 200,000 to 500,000 deaths. The 2009 H1N1 pandemic killed more than 14,000 people worldwide. Meanwhile, public health and bioterrorism concerns are heightened by new mutations of the H5N1 "bird flu" virus, published last week by the journal...

2012-05-07 06:26:47

NEW YORK, May 7, 2012 /PRNewswire/ -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and...

2012-05-04 02:23:24

LONDON, May 4, 2012 /PRNewswire/ -- Existing adoption rates and commercial success of launched Monoclonal Antibodies (mAbs) for therapeutics have established a strong platform for these products. Broadening the horizontal indications for existing mAbs, expanding the applications of mAbs in new therapeutic areas and developing innovative and faster drug delivery mechanism are the current trends in the mAbs market. Monoclonal Antibodies (mAbs) are mono-specific high molecular weight complex...

2012-05-02 10:27:03

REDWOOD CITY, Calif., May 2, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) and OncoMed Pharmaceuticals, Inc. (OncoMed) today announced a strategic alliance to use Next Generation Sequencing (NGS) to identify biomarkers that can be applied to the clinical development of OncoMed's novel antibody cancer therapeutics. Under the terms of the agreement, OncoMed will provide Genomic Health with breast, prostate, colon and lung tumor samples. A subset of these tumors will include...

2012-05-01 02:31:56

SAN DIEGO, May 1, 2012 /PRNewswire/ -- AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced an antibody discovery partnership with Gilead Sciences, Inc. to develop novel antibody therapeutics. (Logo: http://photos.prnewswire.com/prnh/20111205/SF16052LOGO) Under this partnership, antibodies generated by AnaptysBio using its proprietary SHM-XEL platform will be transferred to Gilead for worldwide development and commercialization. Gilead has paid an upfront fee...

2012-04-30 06:24:44

THUNDER BAY, Ontario, April 30, 2012 /PRNewswire/ -- IGY Immune Technology & Life Sciences has acquired manufacturing capabilities to produce its proprietary IgY products. IgY from chicken egg yolks has long been recognized among scientists for its immune enhancing benefits in humans as well as its ability to deliver customized antibodies to fight sickness and maintain good health. Until now, a consistent, purified source has not been available commercially. IGY Immune Technology &...